Chemomab Therapeutics Ltd. (CMMB) Stock Score, Valuation & Financial Research

Chemomab Therapeutics Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CMMB

Chemomab Therapeutics Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 1.40. These figures are a research snapshot, not a buy or sell recommendation.

What Chemomab Therapeutics Ltd. does

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Chemomab Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research and development of its proprietary pipeline of monoclonal antibodies targeting fibro-inflammatory diseases.

Products and services

  • The company's primary product candidate is nebokitug (CM-101), a first-in-class monoclonal antibody designed to neutralize the soluble protein CCL24 to treat fibro-inflammatory conditions such as primary sclerosing cholangitis and systemic sclerosis.

Brands and product families

  • nebokitug (CM-101) — Lead clinical-stage monoclonal antibody candidate for fibro-inflammatory diseases. Source

Customer types

Healthcare providers and patients (potential future market).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract research organizations to conduct clinical trials and contract manufacturing organizations to produce its drug candidates. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company faces competition from various pharmaceutical and biotechnology companies developing treatments for fibro-inflammatory diseases, including those with greater financial, technical, and human resources. Source

Business strengths to evaluate

  • Proprietary pipeline centered on the novel target CCL24 Source
  • Orphan Drug and Fast Track designations for nebokitug Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single lead product candidate, nebokitug Source
  • Requirement for significant additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CMMB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.40
Market capitalization:
8.62M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -7.6M
Free cash flow:
USD -11.22M
Cash:
USD 6M
Total debt:
USD 0.00
EPS:
USD -1.02

What stands out

  • Free cash flow is USD -11.22M, negative for the stored period.
  • The balance sheet shows USD 6M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 6M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CMMB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CMMB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CMMB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CMMB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CMMB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CMMB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.